NCT01259869 - A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 1, 2011

Primary Completion Date

October 29, 2014

Study Completion Date

February 13, 2015

Conditions

Glioblastoma

Interventions

DRUG

PX-866

1 cycle = 8 weeks on study PX-866 - 8mg PO Daily

Trial Locations (7)

Tom Baker Cancer Centre, Calgary

BCCA - Vancouver Cancer Centre, Vancouver

CancerCare Manitoba, Winnipeg

QEII Health Sciences Centre, Halifax

London Regional Cancer Program, London

Univ. Health Network-Princess Margaret Hospital, Toronto

Allan Blair Cancer Centre, Regina